What is Semaglutide?

Weight Loss: In clinical trials, semaglutide has shown remarkable weight loss outcomes. The STEP program (Semaglutide Treatment Effect in People with Obesity) demonstrated that individuals treated with semaglutide achieved an average weight loss of around 15% of their body weight. This is a significant reduction compared to control groups or other weight loss interventions.

A1c Reduction: Semaglutide has been proven effective in reducing A1c levels, which is an indicator of long-term blood sugar control. In clinical studies, patients treated with semaglutide experienced A1c reductions of approximately 1.0% to 1.5% on average.

Improved Glucose Control: Semaglutide has shown consistent efficacy in lowering glucose levels in individuals with type 2 diabetes. Studies have reported reductions in fasting plasma glucose (FPG) and postprandial glucose (PPG) levels, leading to improved glycemic control.

Cardiovascular Benefits: Semaglutide has demonstrated cardiovascular benefits as well. In the SUSTAIN-6 trial, it was found that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by 26% compared to placebo in individuals with type 2 diabetes and high cardiovascular risk.